# Glaukos Corporation (GKOS)

> Glaukos Corporation (GKOS) trades at $237.31 (-0.33%) as of 7:30:06 PM EST on Nov 20, 2026, +34.31% over the past month. Market cap is $14.05B, with 2.9 days to cover in short interest.

Canonical: https://massive.com/quote/gkos
Data as of: 2026-11-21T00:30:06.256Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$237.31** -0.79 (-0.33%)
As of 7:30:06 PM EST on Nov 20, 2026 · 15-minute delayed
NYSE · usd

## Stock performance

How Glaukos Corporation (GKOS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -0.33% |
| 1W | -3.42% |
| 1M | +34.31% |
| YTD | +110.18% |
| 1Y | +142.00% |
| 52-wk range | $93.96 – $255.19 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for GKOS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $233.40 – $244.55 |
| Open | $238.87 |
| Prev close | $238.10 |
| Volume | 1.09M |
| Market cap | $14.05B |
| Shares out | 59.2M |

## Valuation and profitability ratios

Valuation and profitability ratios for Glaukos Corporation: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 20.35 |
| P/B | 19.59 |
| P/FCF | 390.01 |
| ROE | -23.7% |
| ROA | -17.3% |
| Debt/Equity | 0.09 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Glaukos Corporation (GKOS) insider trading](https://massive.com/quote/gkos/insider-trading.md): open-market Form 4 buys and sells by Glaukos Corporation insiders over the last 12 months.

## 8-K filings

Material corporate events Glaukos Corporation has disclosed to the SEC on Form 8-K.

- Nov 6, 2026 · Investor presentation
  “Glaukos Corporation (the "Company") intends to present the materials attached as Exhibit 99.1 to this Current Report on Form 8-K (the "Investor Presentation") from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the investor page of the Company's website at http://investors.glaukos.com.”
- Oct 28, 2026 · Investor presentation
  “A Quarterly Summary containing supplemental business and financial information for the Company's third quarter ended September 30, 2026 is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.”
- Aug 3, 2026 · Investor presentation
  “Glaukos Corporation (the "Company") intends to present the materials attached as Exhibit 99.1 to this Current Report on Form 8-K (the "Investor Presentation") from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the investor page of the Company's website at http://investors.glaukos.com.”
- Jun 3, 2026 · Annual meeting results
  “The annual meeting of stockholders (the "Annual Meeting") of Glaukos Corporation (the "Company") was held on May 28, 2026. At the Annual Meeting, the Company's stockholders voted on three proposals... The final voting results for each matter submitted to a vote of stockholders at the Annual Meeting are as follows: Proposal 1. The election of two Class II directors... Proposal 2. The non-binding advisory vote regarding approval of the compensation of the Company's named executive officers... Proposal 3. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”
- May 4, 2026 · Investor presentation
  “Glaukos Corporation (the "Company") intends to present the materials attached as Exhibit 99.1 to this Current Report on Form 8-K (the "Investor Presentation") from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the investor page of the Company's website at http://investors.glaukos.com.”

## Similar companies

Public companies in a similar business to Glaukos Corporation.

- [ISRG](https://massive.com/quote/isrg.md) Intuitive Surgical Inc. (-2.01%)
- [WST](https://massive.com/quote/wst.md) West Pharmaceutical Services, Inc. (-1.61%)

Daily change in the latest session, 15-minute delayed.

## GKOS short interest

How heavily GKOS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 2.9 |
| Short interest | 4.48M |
| Avg volume | 1.58M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## GKOS news

The latest news and headlines about Glaukos Corporation (GKOS).

- [Here's Why You Should Retain Doximity Stock in Your Portfolio for Now](https://www.zacks.com/stock/news/3033437/here-s-why-you-should-retain-doximity-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-3033437) · Zacks Investment Research · Nov 20, 2026 · neutral sentiment
- [Here's Why You Should Retain Ecolab Stock in Your Portfolio Now](https://www.zacks.com/stock/news/3033360/here-s-why-you-should-retain-ecolab-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-3033360) · Zacks Investment Research · Nov 20, 2026 · neutral sentiment
- [GEHC Advances Manganese-Based MRI Agent to Phase 3 After Positive Data](https://www.zacks.com/stock/news/3033297/gehc-advances-manganese-based-mri-agent-to-phase-3-after-positive-data?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3033297) · Zacks Investment Research · Nov 20, 2026 · positive sentiment
- [GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software](https://www.zacks.com/stock/news/3032753/ge-healthcare-wins-fda-nod-for-ai-feeding-tube-detection-software?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3032753) · Zacks Investment Research · Nov 19, 2026 · positive sentiment
- [Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now](https://www.zacks.com/stock/news/3032612/here-s-why-you-should-retain-neuropace-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-3032612) · Zacks Investment Research · Nov 19, 2026 · neutral sentiment

## About Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

| Measure | Value |
| --- | --- |
| Exchange | NYSE |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 1.09K |
| Listed | Jun 25, 2015 |

[Company website](https://www.glaukos.com)

## FAQ

### What is the Glaukos Corporation (GKOS) stock price today?

Glaukos Corporation (GKOS) is trading at $237.31 (-0.33% on the day) as of 7:30:06 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Glaukos Corporation?

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases.

### What is the short interest in GKOS?

As of Oct 30, 2026, GKOS has 4.48M shares short and 2.9 days to cover.

### What exchange is GKOS listed on?

Glaukos Corporation (GKOS) trades on NYSE in USD, in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry.

## Live data

Prices here are 15-minute delayed. For real-time GKOS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=GKOS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Glaukos Corporation (GKOS) insider trading](https://massive.com/quote/gkos/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
